These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7850293)

  • 1. Radical radiotherapy for localized adenocarcinoma of the prostate. A report of 191 cases.
    el-Galley RE; Howard GC; Hawkyard S; Klys H; Kerr GR; Duncan W; Chisholm GD; Fowler JW
    Br J Urol; 1995 Jan; 75(1):38-43. PubMed ID: 7850293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy.
    Zagars GK; Ayala AG; von Eschenbach AC; Pollack A
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):237-45. PubMed ID: 7836075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer.
    Petrovich Z; Lieskovsky G; Langholz B; Jozsef G; Streeter OE; Skinner DG
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):600-9. PubMed ID: 12062603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy.
    Chauvet B; FĂ©lix-Faure C; Lupsascka N; Fijuth J; Brewer Y; Davin JL; Kirscher S; Reboul F
    J Clin Oncol; 1994 Jul; 12(7):1402-7. PubMed ID: 7517443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carcinoma of the prostate: results of radical radiotherapy (1970-1985).
    Duncan W; Warde P; Catton CN; Munro AJ; Lakier R; Gadalla T; Gospodarowicz MK
    Int J Radiat Oncol Biol Phys; 1993 May; 26(2):203-10. PubMed ID: 8491678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987.
    Steinberg GD; Epstein JI; Piantadosi S; Walsh PC
    J Urol; 1990 Dec; 144(6):1425-32. PubMed ID: 1700157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.
    Le QT; Fu KK; Kaplan M; Terris DJ; Fee WE; Goffinet DR
    Cancer; 1999 Nov; 86(9):1700-11. PubMed ID: 10547542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
    Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
    Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer.
    Wang YJ; Huang CY; Hou WH; Wang CC; Lan KH; Chen CH; Yu HJ; Lai MK; Cheng AL; Liu SP; Pu YS; Cheng JC
    World J Surg Oncol; 2015 Nov; 13():312. PubMed ID: 26545980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
    Zagars GK
    J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
    Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors.
    Martinez A; Gonzalez J; Spencer W; Gustafson G; Kestin L; Kearney D; Vicini FA
    J Urol; 2003 Mar; 169(3):974-9; discussion 979-80. PubMed ID: 12576825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
    Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
    Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic importance of Gleason 7 disease among patients treated with external beam radiation therapy for prostate cancer: results of a detailed biopsy core analysis.
    Spratt DE; Zumsteg Z; Ghadjar P; Pangasa M; Pei X; Fine SW; Yamada Y; Kollmeier M; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1254-61. PubMed ID: 23182392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy.
    Zagars GK; von Eschenbach AC; Ayala AG
    Cancer; 1993 Sep; 72(5):1709-25. PubMed ID: 7688659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [External radiotherapy with curative intent for adenocarcinoma clinically localized to the prostate (T1 to T3N0M0): intermediate results with a minimum follow-up of 4 years].
    Rohner S; Bieri S; Graber P
    Ann Urol (Paris); 1994; 28(4):221-8. PubMed ID: 7979212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.